Calico Life Sciences Announces Fosigotifator Granted Breakthrough Therapy Designation by the U.S. FDA for the Treatment of Vanishing White Matter Disease

Vanishing White Matter Disease (VWMD)

https://www.calicolabs.com/press/calico-life-sciences-announces-fosigotifator-granted-breakthrough-therapy-designation-by-the-u-s-fda-for-the-treatment-of-vanishing-white-matter-disease

Calico have been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for Fosigotifator, a potential treatment for Vanishing White Matter (VWM) disease. Breakthrough Therapy designation is intended to speed up the review of medicines that treat a serious or life-threatening condition and have shown preliminary clinical evidence indicating the potential for substantial improvement over available therapies.